Skip to content

MBX Biosciences, Inc. MBX Operating Income

Operating Income at other companies

Amgen logo
AmgenAMGN
$2.67B+126%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$164.13M-196%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
-$43.78M-15.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$105.96M-1.5%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$92.5M-47.1%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
-$140.38M-26.0%

Other financials

Income statement

See full
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.21B+475%
Enterprise value$2.16B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s operating income?
MBX Biosciences, Inc. (MBX) reported operating income of -$27.27M in Q1 2026.
How has MBX Biosciences, Inc.'s operating income changed year-over-year?
MBX Biosciences, Inc.'s operating income decreased by 2.8% year-over-year, from -$26.53M to -$27.27M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.